LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Boothbay Fund Management LLC

Boothbay Fund Management LLC trimmed its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 26.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,746 shares of the company's stock after selling 14,633 shares during the quarter. Boothbay Fund Management LLC owned 0.14% of LENZ Therapeutics worth $1,147,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in LENZ Therapeutics by 5.3% during the 4th quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company's stock worth $34,022,000 after acquiring an additional 59,630 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of LENZ Therapeutics by 83.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company's stock valued at $23,760,000 after purchasing an additional 374,326 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in LENZ Therapeutics by 3.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 127,196 shares of the company's stock valued at $3,672,000 after buying an additional 3,825 shares during the period. Harbor Capital Advisors Inc. purchased a new position in LENZ Therapeutics during the fourth quarter valued at approximately $1,270,000. Finally, American Century Companies Inc. raised its stake in LENZ Therapeutics by 36.2% in the fourth quarter. American Century Companies Inc. now owns 32,506 shares of the company's stock worth $938,000 after buying an additional 8,631 shares in the last quarter. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. Piper Sandler started coverage on LENZ Therapeutics in a research report on Monday, April 14th. They set an "overweight" rating and a $51.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $38.00 target price on shares of LENZ Therapeutics in a research note on Wednesday, April 16th. Citigroup boosted their target price on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a report on Thursday, March 20th. Finally, TD Cowen began coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 price target on the stock. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $46.60.

LENZ Therapeutics Stock Performance

NASDAQ:LENZ traded up $0.37 during mid-day trading on Thursday, hitting $28.88. 247,573 shares of the company's stock traded hands, compared to its average volume of 184,857. The company has a fifty day moving average of $23.79 and a 200 day moving average of $27.24. LENZ Therapeutics, Inc. has a twelve month low of $14.42 and a twelve month high of $38.93. The company has a market capitalization of $795.44 million, a P/E ratio of -6.05 and a beta of 0.43.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, research analysts expect that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.